Epidemiology shows di (2-ethylhexyl) phthalate disrupts metabolic pathways in obesity, suggesting new therapeutic interventions.
DEHP exposure promotes CKM syndrome through coordinated disruption of metabolic (PPARG), inflammatory (PTGS2), and fibrotic (MMP2) pathways, with obesity serving as a critical effect modifier. The integrated computational and experimental evidence provides a mechanistic basis for future therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: